Table of Contents
Volume 3 | Issue 1
Publication Date: August 2001- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
11 |
Individualized Therapy for Non–Small-Cell Lung Cancer Chandra P. Belani |
|
Meeting Highlights | ||
12-17 |
Highlights From: 37th Annual American Society of Clinical Oncology Meeting, San Francisco, CA Angelia D. Gibson, Kavita Maung |
|
Researches in Brief | ||
21-24 |
Individualizing Chemotherapy for Treatment of Non–Small-Cell Lung Cancer Based on Genetic Profiling of Tumors and Patients Amy I. D’Orazio |
|
25-26 |
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Gene-Transduced Tumor Vaccines (GVAX™) in Non–Small-Cell Lung Cancer Kavita Maung, John Nemunaitis, Casey Cunningham |
|
Comprehensive Review | ||
27-32 |
ZD1839 (Iressa™) In Non–Small-Cell Lung Cancer Roy S. Herbst, Fadlo R. Khuri, Frank V. Fossella, Bonnie S. Glisson, Merrill S. Kies, Katherine M. Pisters, Jeanne R. Riddle, Karen A. Terry, Jin Soo Lee |
|
Original Contributions | ||
33-36 |
The Relevance of the Revised Version of the International Lung Cancer Staging System for Non–Small-Cell Lung Cancer Treated with Radiotherapy Hans Langendijk, Jos de Jong, Rinus Wanders, Ben Slotman |
|
37-41 |
Photodynamic Therapy for Patients with Advanced Non–Small-Cell Carcinoma of the Lung Blanding U. Jones, Mohammad Helmy, Matthew Brenner, Dan L. Serna, Jim Williams, John C. Chen, Jeffrey C. Milliken |
|
Commentary | ||
42 |
Commentary on “Photodynamic Therapy for Patients with Advanced Non–Small-Cell Carcinoma of the Lung” David Ost |
|
Original Contribution | ||
43-46 |
Phase II Study of Sequential Treatment of Advanced Non–Small-Cell Lung Cancer: Three Cycles of High-Dose Epirubicin Plus Cisplatin Followed by Weekly Vinorelbine Monica Guaraldi, Antonella Marino, Franco Pannuti, Gildino Farabegoli, Andrea Martoni |
|
Commentary | ||
47-48 |
Commentary on “Phase II Study of Sequential Treatment of Advanced Non–Small-Cell Lung Cancer: Three Cycles of High-Dose Epirubicin Plus Cisplatin Followed by Weekly Vinorelbine” Martin J. Edelman |
|
Translational Medicine | ||
49-57 |
Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer Martin Palmer, Joanne Parker, Shanu Modi, Charlie Butts, Mike Smylie, Allison Meikle, Mairead Kehoe, Grant MacLean, Mike Longenecker |
|
Commentary | ||
58 |
Commentary on “Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer” Kathy Schiffman, Mary L. Disis |
|
Translational Medicine | ||
59-64 |
Clinical Utility of PET-FDG Imaging in Differentiation of Benign from Malignant Adrenal Masses in Lung Cancer Naresh C. Gupta, Geoffrey M. Graeber, Wael J. Tamim, John S. Rogers, Liezl Irisari, Harry A. Bishop |
|
Brief Communication | ||
65-68 |
Intraluminal Brachytherapy for Malignant Endobronchial Tumors: An Update on Low-Dose Rate Versus High-Dose Rate Radiation Therapy Theodore C.M. Lo, John F. Beamis, Jr, Andrew G. Villanueva, Anthony W. Gray, Jr, Timothy R. Wu |
|
Commentary | ||
69-70 |
Commentary on “Intraluminal Brachytherapy for Malignant Endobronchial Tumors: An Update on Low-Dose Rate Versus High-Dose Rate Radiation Therapy” Laurie E. Gaspar |
|